Pacira BioSciences, Inc.
$ 23.46
0.21%
25 Feb - close price
- Market Cap 1,007,128,000 USD
- Current Price $ 23.46
- High / Low $ 23.68 / 23.04
- Stock P/E 49.81
- Book Value 16.93
- EPS 0.47
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.03 %
- 52 Week High 27.64
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$29.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0 | 0.7 | -0.11 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 | 0.78 | 0.53 |
| Estimated EPS | 0.9017 | 0.65 | 0.72 | 0.5971 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.88 | 0.78 | 0.76 | 0.62 |
| Surprise | -0.9017 | 0.05 | -0.83 | 0.0229 | 0.0797 | 0.09 | 0.19 | 0 | 0.01 | -0.06 | 0.02 | -0.09 |
| Surprise Percentage | -100% | 7.6923% | -115.2778% | 3.8352% | 9.5989% | 12.8571% | 27.1429% | 0% | 1.1364% | -7.6923% | 2.6316% | -14.5161% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-02-25 01:52:46
Pacira Biosciences, Inc. has seen a slight decline in its stock price, trading at $23.11, amidst mixed technical indicators and significant market volatility over the past year. While the company has outperformed the S&P 500 in the short term, its long-term performance demonstrates considerable declines, highlighting challenges over extended periods. Technical analyses show a mix of bearish and bullish signals, with notable underperformance compared to the S&P 500 when looking at year-to-date and multi-year returns.
2026-02-22 06:36:31
This article discusses the importance of reducing opioid use in pediatric post-operative care due to misuse risks, side effects, and negative impacts on recovery. Rady Children's Hospital has successfully implemented multimodal non-opioid pain management protocols, including the use of EXPAREL, which have led to significant reductions in opioid use, enhanced patient recovery, and improved pain scores. The author emphasizes the benefits of locally targeted pain relief and patient education regarding non-opioid alternatives.
2026-02-19 08:58:19
Pacira BioSciences (PCRX) is expected to report its Q4 2025 earnings after market close on Thursday, February 26, 2026, with analysts projecting earnings of $0.85 per share and revenues of $201.93 million. Recent insider activity shows sales by CFO Shawn Cross and SVP Lauren Riker, totaling 30,416 shares sold in the last three months. The stock currently trades around $23, holds a "Hold" consensus rating from analysts, and has an average price target of $30.75.
2026-02-15 15:08:00
This article analyzes Pacira Biosciences Inc. (PCRX), highlighting a mid-channel oscillation pattern and strong near-to-mid-term sentiment that could extend long-term. It provides three AI-generated trading strategies including position trading, momentum breakout, and risk hedging, with specific entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
2026-02-13 11:57:14
Rosen Law Firm announces a class action lawsuit on behalf of purchasers of Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023, and August 8, 2024. Investors who purchased Pacira securities during this period may be entitled to compensation due to alleged false and misleading statements made by the company regarding its patent protections for the drug Exparel. The lawsuit claims that Pacira created a false impression of strong patent protections when they were, in fact, fragile, leading to investor damages.
2026-02-13 05:57:14
Pacira BioSciences (NASDAQ:PCRX) has seen its share price decline by 8.6% over three months, despite its mixed financials. The company's low Return on Equity (ROE) of 2.9%, compared to an industry average of 22%, combined with a 61% net income decline over five years, suggests underlying issues with capital allocation or earnings retention. Although past performance is weak, analysts anticipate future earnings growth for Pacira BioSciences.
